Bernstein just added new fuel to Eli Lilly’s (LLY) endless rally, as the company raised its stock price target to $1,300 from $1,100.
For perspective, this is an 18% increase compared to the previous target, although it represents a 21% to 22% advantage compared to Lilly’s current stock price.
Analyst Courtney Breen believes Wall Street is still not taking into account how massive the company’s next wave of GLP-1 catalysts could be.
She feels that Lilly’s incredible leap into the trillion-dollar club, as reported by Reuters, was not the best, and that 2026 could be the turning point where its illustrious history transitions into genuine “churn and rise” momentum.
Additionally, with the imminent launch of orforglipron, White House policy is moving toward broader coverage, while tirzepatide has evolved into a multi-indication platform.
Breen therefore sees a setup that offers many advantages.
Furthermore, it is important to note that according to Tipranks, Breen wears a standout 94% success rateand 32 of his 34 stock options turned a profit.
In addition to that, their recommendations offer solid +21.5% average return per qualificationpositioning her among Wall Street’s top analysts.
Bernstein’s Courtney Breen significantly raised Eli Lilly’s price target, citing stronger GLP-1 catalysts ahead.Photo by NurPhoto on Getty Images
Bernstein analyst Breen’s optimism about Eli Lilly is largely based on what she calls an “incredibly rich” catalyst path spanning more than two years.
Most of it is due to how much earnings power Mr. Market hasn’t modeled into the stock.
At the center is Lilly’s oral GLP-1. orforglipronwhich Breen believes will drive the company’s next stage of expansion.
More Medicare/Medicaid
This is partly due to a favorable political context in the United States that has changed President Donald Trump’s GLP-1 agreement, along with growing global reimbursement channels.
Breen and his team developed a financial model that breaks down Medicare, Medicaid, commercial and cash demand into a quarterly schedule that spans 2027 and annually to 2030.
The results showed that the consensus was still too conservative regarding volumes and potential sales.
Related: Cathie Wood Buys the Dip in Nvidia-Backed Stocks
The breakthrough is expected to occur in 2026.
This is when orforglipron goes from being a promise to becoming a profit driver, with estimated sales at an excellent level. 1.8 billion dollarswhich is more than 3 times the street view of $550 million.
What is even more impressive is that Breen emphasizes that these high figures are US-only assumptions based on almost 80,000 scripts per week in the oral obesity market.